Choroidal dystrophy+1
Not recruitingLong-term Safety and Efficacy Study of Gene Therapy for Choroideremia and X-Linked Retinitis Pigmentosa Using AAV2-REP1 and AAV8-RPGR in Previously Treated Patients
Long-term Safety and Efficacy Study of Gene Therapy for Choroideremia and X-Linked Retinitis Pigmentosa Using AAV2-REP1 and AAV8-RPGR in Previously Treated Patients
- Disease:Choroidal dystrophyRetinitis pigmentosa
- Substances:Timrepigene Emparvovec
France- Participants:18–64 years
- Substances:Timrepigene Emparvovec
- Sponsor:Biogen Idec Research Limited

